Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Gene behind Vel blood group discovered

Researchers have uncovered the gene at the root of a human blood group that has remained a mystery for the past 60 years. They showed that a genetic deletion on this gene is responsible for the lack of this blood group in some people.

8 Apr 2013

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.

8 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013

Emergent BioSolutions provides update on TRU-016 Phase 1b study

Emergent BioSolutions Inc. today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia.

5 Apr 2013

FDA clears ERYTECH Pharma' IND to start Phase I clinical trial of ERYASP in patients with ALL

ERYTECH Pharma SA announced today that it has received clearance of its Investigational New Drug Application from the United States Food and Drug Administration to initiate a Phase I clinical trial of its product ERYASP, L-asparaginase loaded erythrocytes, in patients 40 years or older with newly diagnosed Acute Lymphoblastic Leukemia.

4 Apr 2013

Women experiencing still birth are more likely to develop blood clots, says study

Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.

3 Apr 2013

Doctors give new hope for leukemia patients

Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too.

3 Apr 2013

Pregnancy-related events increase women's risk of deadly blood clot: Study

Newly identified pregnancy-related events, such as stillbirth or pre-term birth, may dramatically increase a woman's risk of developing a potentially deadly blood clot immediately after pregnancy, according to the results of a large, population-based study published online today in Blood, the Journal of the American Society of Hematology.

3 Apr 2013

Study: Pradaxa drug may increase risk and severity of viral infections

A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults.

2 Apr 2013

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

28 Mar 2013

Novel cell therapy effective in treating aggressive form of childhood leukemia

Two children with an aggressive form of childhood leukemia had a complete remission of their disease—showing no evidence of cancer cells in their bodies—after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells.

26 Mar 2013

Study links inherited variations in few genes to increased risk of pediatric leukemia

Humans have between 20,000 and 25,000 genes that carry instructions for assembling the proteins that do the work of cells. Work led by St. Jude Children's Research Hospital found that children who inherit certain variations in four particular genes are at much higher risk of developing acute lymphoblastic leukemia.

20 Mar 2013

Mesenchymal stem cells safe, effective for treating poor graft function: Study

When a research team in China evaluated the efficacy and safety of using mesenchymal stem cells expanded from the bone marrow of non-self-donors to treat patients experiencing poor graft function after receiving transplants of non-self-donated blood stem cells (allo-HSCT), they found that the mesenchymal stem cells were both safe and effective for treating primary and secondary PGF.

19 Mar 2013

Umbilical cord blood stem cell transplants may be an effective alternative to treat Hurler's syndrome

Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Mar 2013

CHOP expert to receive Pediatric Oncology Award from ASCO

The American Society of Clinical Oncology today announced it will confer one of its highest awards on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children's Hospital of Philadelphia.

16 Mar 2013

Advanced gene sequencing test helps clinicians treat cancer

The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.

14 Mar 2013

B cells regulate obesity-associated inflammation and T2D through two specific mechanisms

New research from Boston University School of Medicine (BUSM) reveals that B cells regulate obesity-associated inflammation and type 2 diabetes through two specific mechanisms.

13 Mar 2013

NCI-sponsored study to evaluate rosuvastatin for prevention of colon cancer

With March designated as Colorectal Cancer Awareness Month, the North Shore-LIJ Cancer Institute is enrolling people who were recently treated for colon cancer in a polyp prevention study. This National Cancer Institute (NCI)-sponsored study evaluates the cholesterol drug, rosuvastatin (Crestor), as a treatment to reduce the risk of colon cancer.

11 Mar 2013